Investment Thesis
Vistagen is a pre-clinical stage biotech company in severe financial distress with 54% YoY revenue collapse and $50.2M annual cash burn, leaving only ~1 year of runway despite $47.4M in cash reserves. With no revenue generation capability and operating losses exceeding $55M, the company faces critical funding pressure and dilution risk.
Strengths
- Maintains $47.4M cash reserve to fund operations
- Zero debt burden eliminates leverage risk
- Strong current ratio of 4.67x provides short-term liquidity buffer
Risks
- Revenue collapsed 54% YoY on minimal $804K base; business fundamentals severely deteriorating
- Annual operating losses of $55.4M and cash burn of $50.2M implies ~1 year cash runway
- Extreme negative margins (-6891% operating, -6643% net) indicate pre-clinical stage with no viable commercial products
Key Metrics to Watch
- Monthly cash burn rate and months of runway remaining
- Revenue trends and clinical trial progress or product partnership announcements
- Financing activity and potential shareholder dilution events
Financial Metrics
Revenue
804.0K
Net Income
-53.4M
EPS (Diluted)
$-1.46
Free Cash Flow
-50.2M
Total Assets
65.1M
Cash
47.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-6,891.7%
Net Margin
-6,643.2%
ROE
-104.9%
ROA
-82.1%
FCF Margin
-6,248.3%
Balance Sheet & Liquidity
Current Ratio
4.67x
Quick Ratio
4.67x
Debt/Equity
0.00x
Debt/Assets
21.7%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T22:12:24.296251 |
Data as of: 2025-12-31 |
Powered by Claude AI